IVZ trades 6.8% below Wall Street's consensus target of $30.06.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IVZ achieves its forward estimates and maintains a stable P/E multiple of 10.9x. This scenario reflects the blended consensus of 28 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Invesco Ltd. (IVZ) has a Wall Street consensus price target of $30.06, based on estimates from 28 covering analysts. With the stock currently trading at $28.14, this represents a potential upside of +6.8%. The company has a market capitalization of $12.50B.
Analyst price targets range from a low of $26.00 to a high of $34.50, representing a 28% spread in expectations. The median target of $30.50 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 12 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IVZ trades at a trailing P/E of -17.6x and forward P/E of 10.9x. Analysts expect EPS to grow +580.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $12.23, with bear and bull scenarios of $7.70 and $16.11 respectively. Model confidence stands at 47/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
BENFranklin Resources, Inc. | $17.2B | $33.05 | $32.00 | -3.2% | Hold | 12.1x | 27 |
TROWT. Rowe Price Group, Inc. | $23.4B | $107.65 | $102.60 | -4.7% | Hold | 11.3x | 38 |
AMGAffiliated Managers Group, Inc. | $9.4B | $352.90 | $402.50 | +14.1% | Buy | 10.1x | 12 |
VRTSVirtus Investment Partners, Inc. | $948M | $141.60 | $135.67 | -4.2% | Hold | 5.8x | 11 |
DHILDiamond Hill Investment Group, Inc. | $473M | $174.99 | — | — | — | 9.5x | — |
BLKBlackRock, Inc. | $173.7B | $1050.09 | $1301.63 | +24.0% | Buy | 19.7x | 33 |
STTState Street Corporation | $48.6B | $168.31 | $161.50 | -4.0% | Buy | 13.5x | 37 |
APAMArtisan Partners Asset Management Inc. | $2.5B | $35.88 | $41.00 | +14.3% | Hold | 9.4x | 15 |
MORNMorningstar, Inc. | $5.8B | $153.68 | $227.67 | +48.1% | Hold | 12.9x | 6 |
SCHWThe Charles Schwab Corporation | $160.7B | $91.70 | $121.89 | +32.9% | Buy | 14.9x | 50 |
Quick answers to the most common questions about buying IVZ stock.
The consensus price target for IVZ is $30.06, close to the current price of $28.135 (6.8% implied move). Based on 28 analyst estimates, the stock appears fairly valued near current levels.
IVZ has a consensus rating of "Hold" based on 28 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $30.06 implies 6.8% upside from current levels.
With a forward P/E of 10.908x, IVZ trades at a relatively low valuation. The consensus target of $30.06 implies 6.8% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $34.5 for IVZ, while the most conservative target is $26. The consensus of $30.06 represents the median expectation. Our quantitative valuation model projects a bull case target of $16 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IVZ is heavily covered by Wall Street, with 28 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 16 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IVZ stock forecast based on 28 Wall Street analysts shows a consensus price target of $30.06, with estimates ranging from $26 (bear case) to $34.5 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $12, with bear/bull scenarios of $8/$16.
Our quantitative valuation model calculates IVZ's fair value at $12 (base case), with a bear case of $8 and bull case of $16. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 47/100.
IVZ trades at a forward P/E ratio of 10.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
IVZ appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $30.06 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IVZ analyst price targets range from $26 to $34.5, a 28% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30.06 consensus represents the middle ground. Our model's $8-$16 range provides an independent fundamental perspective.
Deep dive into IVZ consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.